Mitchell Shirvan and Meir Bialer

Serial No.: 09/932,370

Filed :

August 17, 2001

Page 2

1. (Amended) A method of treating a subject suffering from pain comprising periodically administering to the subject a therapeutically effective dose of a compound having the following structure:

 $\bigcap_{N} R_1 \bigcap_{(CH_2)n} O$ NR_2R

 R_4

or

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; wherein the therapeutically effective dose is 1,000 to 6,000 mg; so as to thereby treat the subject's pain.

- 16. (Amended) The method of claim 1, wherein the therapeutically effective dose is an amount from 1,000 mg to 4,000 mg.
- 17. (Amended) The method of claim 16, wherein the therapeutically effective dose is an amount from 1,000 mg to 3,000 mg.

(i)

Gr

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 3

18. (Amended) The method of claim 17, wherein the therapeutically effective dose is an amount from 2,000 mg to 3,000 mg.

(ir

- 19. (Amended) The method of claim 18, wherein the therapeutically effective dose is 3,000 mg.
- 20. (Amended) The method of claim 18, wherein the therapeutically effective dose is 1,000 mg.
- 21. (Amended) The method of claim 20, wherein the therapeutically effective dose is 2,000 mg.

03

- 26. (Amended) The method of claim 22, wherein one or more of R_1 , R_2 , or R_3 is a linear chain C_1 - C_6 alkyl group.
- 27. (Amended) The method of claim 22, wherein one or more of R_1 , R_2 , or R_3 is a branched chain $C_1 C_6$ alkyl group.
- 40. (Amended) The method of claim 22, wherein the therapeutically effective dose is an amount from 1,000 mg to 4,000 mg.
- 41. (Amended) The method of claim 40, wherein the therapeutically effective dose is an amount from 1,000 mg to 3,000 mg.
- 42. (Amended) The method of claim 41, wherein the therapeutically effective dose is an amount from 2,000 mg to 3,000 mg.
- 43. (Amended) The method of claim 42, wherein the therapeutically effective dose is 3,000 mg.
- 44. (Amended) The method of claim 42, wherein the therapeutically effective dose is 1,000 mg.

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 4

Cirkler.X

45. (Amended) The method of claim 44, wherein the therapeutically effective dose is 2,000 mg.

47. (Amended) A method of pain prophylaxis in a subject predisposed to suffering from pain comprising periodically administering to the subject a prophylactically effective dose of a compound having the following structure:

$$\bigcap_{N \in \mathbb{R}_4} \bigcap_{(CH_2)n} \bigcap_{NR_2R_3}$$

or

$$\bigcap_{N \text{ (CH}_2)n} \bigcap_{NR_2R_3}$$

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; wherein the prophylactically effective dose is 1,000 to 6,000 mg; and wherein the pain is neuropathic pain, a migraine or a headache disorder; so as to thereby effect pain prophylaxis in the subject.

45

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 5

55. (Amended) The method of claim 47, wherein the pain is neuropathic pain.

- 62. (Amended) The method of claim 47, wherein the prophylactically effective dose is an amount from 1,000 mg to 4,000 mg.
- 63. (Amended) The method of claim 62, wherein the prophylactically effective dose is an amount from 1,000 mg to 3,000 mg.
- 64. (Amended) The method of claim 63, wherein the prophylactically effective dose is an amount from 2,000 mg to 3,000 mg.
- 65. (Amended) The method of claim 64, wherein the prophylactically effective dose is 3,000 mg.
- 66. (Amended) The method of claim 64, wherein the prophylactically effective dose is 1,000 mg.
- 67. (Amended) The method of claim 66, wherein the prophylactically effective dose is 2,000 mg.

Cid

- 72. (Amended) The method of claim 68, wherein one or more of R_1 , R_2 , or R_3 is a linear chain $C_1 C_6$ alkyl group.
- 73. (Amended) The method of claim 68, wherein one or more of R_1 , R_2 , or R_3 is a branched chain $C_1\text{-}C_6$ alkyl group.
- G9
- 86. (Amended) The method of claim 68, wherein the prophylactically effective dose is an amount from 1,000 mg to 4,000 mg.

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 6

87. (Amended) The method of claim 86, wherein the prophylactically effective dose is an amount from 1,000 mg to 3,000 mg.


88. (Amended) The method of claim 87, wherein the prophylactically effective dose is an amount from 2,000 mg to 3,000 mg.

89. (Amended) The method of claim 88, wherein the prophylactically effective dose is 3,000 mg.

90. (Amended) The method of claim 88, wherein the prophylactically effective dose is 1,000 mg.

91. (Amended) The method of claim 90, wherein the prophylactically effective dose is 2,000 mg.

93. (Amended) A method of treating a subject suffering from pain comprising periodically administering to the subject a pharmaceutical composition comprising a therapeutically effective dose a compound having the following structure:



Applicants: Mitchell Shirvan and Meir Bialer

Serial No.: 09/932,370

Filed : August 17, 2001

Page 7

$$\bigcap_{\substack{N\\R_4}} \bigcap_{(CH_2)n} \bigcap_{NR_2R_3}$$

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, and a pharmaceutically acceptable carrier; wherein the therapeutically effective dose is 1,000 to 6,000 mg; and wherein the pain is neuropathic pain, a migraine or a headache disorder; so as to thereby treat the subject's pain.

94. (Amended) A method of pain prophylaxis in a subject predisposed to suffering from pain comprising periodically administering to the subject a composition comprising a prophylactically effective dose of a compound having the following structure:

(Vig

Applicants: Mitchell Shirvan and Meir Bialer

Serial No.: 09/932,370

Filed: August 17, 2001

Page 8

$$\bigcap_{\substack{N\\R_4}} \bigcap_{(CH_2)n} \bigcap_{NR_2R_3}$$

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3, and a pharmaceutically acceptable carrier; wherein the therapeutically effective dose is 1,000 to 6,000 mg; and wherein the pain is neuropathic pain, a migraine or a headache disorder; so as to thereby effect pain prophylaxis in the subject.

95. (Amended) A method of treating a subject suffering from a headache disorder comprising periodically administering to the subject a therapeutically effective dose of a compound having the following structure:

$$\bigcap_{\substack{N\\R_4}} \bigcap_{(CH_2)n} \bigcap_{NR_2R_3}$$

Applicants: Mitch

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 9

$$\bigcap_{\substack{N\\R_4}} \bigcap_{(CH_2)n} \bigcap_{NR_2R_3}$$

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; wherein the therapeutically effective dose is 1,000 to 6,000 mg; so as to thereby treat the headache disorder.

(Jid

96. (Amended) A method of preventing a headache disorder in a subject predisposed to suffering from a headache disorder comprising periodically administering to the subject a prophylactically effective dose of a compound having the following structure:

or

$$N$$
 R_4
 $(CH_2)n$
 NR_2R_3

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 10

wherein R_1 , R_2 , R_3 and R_4 are independently the same or different and are hydrogen, a linear or branched C_1 - C_6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; wherein the prophylatically effective dose is 1,000 to 6,000 mg; so as to thereby prevent the headache disorder in the subject.

97. (New) The method of claim 95, wherein the headache disorder is a migraine, cluster headache, tension-type headache, or miscellaneous-type headache.

98. (New) The method of claim 97, wherein the headache disorder is a cluster headache, tension-type headache, or miscellaneous-type headache.

99. (New) The method of claim 96, wherein the headache disorder is a migraine, cluster headache, tension-type headache, or miscellaneous-type headache.

100. (New) The method of claim 99, wherein the headache disorder is a cluster headache, tension-type headache, or miscellaneous-type headache.

101. (New) The method of claim 8, wherein the somatogenic pain is cancer pain, postoperative pain, low back pain, complex regional pain syndrome, phantom pain, HIV pain, osteoarthritis pain or rheumatoid arthritis pain.

102. (New) The method of claim 101, wherein the somatogenic pain is low back pain, complex regional pain syndrome, or osteoarthritis pain.

Gib

Mitchell Shirvan and Meir Bialer

Serial No.:

09/932,370

Filed

August 17, 2001

Page 11

103. (New) The method of claim 9, wherein the neuropathic pain is diabetic peripheral neuropathy, postherpetic neuralgia, or trigeminal neuralgia.

(Lu

104. (New) The method of claim 24, wherein the periodic administration is effected six times a day.

105. (New) The method of claim 70, wherein the periodic administration is effected six times a day.